به نام خدا
CURRICULUM VITAE
Dr, M.Mirakhorli, Medical Genetics, PhD,
UPM University of Malaysia
Experience:
Genetic Clotting Disorders; carrier detection, PGD &PND in Hemophilia A&B,
Types of von Willebrand disorder VWD, Glanzmann thrombasthenia, deficiency in Factors 2, 5,
7,8, 9, 10,13
Thrombophilia panel,
Cancer; Colorectal cancer and breast cancer
HLA analysis,
Infertility,
Karyotype in BS & AF,
PUBLICATION
Genetic alternation and inhibitor development in Iranian patients with hemophilia A ‘A Report
from a Large Hemophilia Center in the IRAN’. mirakhorli and etal undersubmission
Frequency of Type 2N vWD Among patients with Mild or Moderate Factor VIII Deficiency in
an 18-month period in Iran. Azari.B, Mirakhorli M, Ahmadinejad M.
-Genetics analysis of non-severe hemophilia A phenotype with a discrepancy between one-stage
and chromogenic factor VIII activity assays. Valikhani A, Mirakhorli M etal. Transfus Apher
Sci.2021; 60(5): 103194.
-Clinical and molecular characterization of Iranian patients wi th congenital fibrinogen disorder.
Mohsenian M, Mirakkhorli M, etal. Transfus Apher Sci. 2021;60(6):103203.
-Factor XIII mutation spectrum in Iranian patients with Hereditary Factor XIII Deficiency:
detection of three novel mutations. M.Mirakhorli, Baghaeipoor.M, et al, International Journal of
Laboratory Hematology, 2019; 41(3): 61-65.
-Haplotype analysis of DXS548 and FRAXAC1 microsatellite loci in Iranian patients with
Fragile X Syndromes. Aleyasin SA, Salamat F, Mirakhori M. Iran J Child Neurol.2018;12(1):37-
46.
– Isolation and Characterization of a New Cell Line of Retinoblastoma. Ghassemi F, Heidari
Keshe S, Mirakhorli M, et al. PeerJ Preprints, 2017.
-A Common Promoter Polymorphism (-23HphI) in Insulin Gene and Susceptibility to Colorectal
Cancer. Nobakht H. Mahmoudi T, Mirakhorli M, et al. Int J Cancer Manag. 2017:10(6): 1-6.
-Lack of association between P-gp and MRP 1 expression and clinical outcomes in Iranian
retinoblastoma. Mirakhorli M, Ghassemi F, Asadi F. Iranian journal of ophthalmology. 2014
26(1).
-Resistin -420C>G promoter variant and colorectal cancer risk. Mahmoudi T, Karimi KH,
Arkani M, Farahani H, Vahedi M, Dabiri R, Nobakht H, Asadi A, Mirakhorli M,et al. Int J Biol
Markers. 2014 ;29(3): 233-8.
– Association of vitamin D receptor gene variants with polycystic ovary syndrome: A case
control study. Mahmoudi T, Majidzadeh T, Farahani H, Mirakhorli M, et al. Int J Reprod
BioMed. 2015.13(12): 793-800.
-MicroRNAs Horizon in Retinoblastoma. Mirakhorli M, Mahmoudi T, Heidari M. 2013.
51(12):823-829. Acta Medica Iranica.
-Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in
patients receiving adjuvant FOLFOX-4 chemotherapy. Mirakhorli M, Rahman SA, Abdullah S,
Vakili M, Rozafzon R, Khoshzaban A. Mol Med Report. 2013 Feb;7(2):613-7.
-No association between immunohisthocemical expression of MRP2 and early relapse in
colorectal cancer patients treated with FOLFOX-4. Mirakhorli M, Shayanfar N, Rahman SA and
et al. Oncol lett, 2012; 4, 893-7.
-Association of the MTHFR C677T polymorphism and fragile X syndrome in an Iranian
population. Aleyasin A, Mirakhorli M. Neurology Asia 2012; 17(4): 347-352.
-Common Polymorphism A1298C in Methylenetetrahydrofolate Reductase Gene Is not a Risk
Factor for Coronary Artery Disease in Selected Iranian Patients. Ghaedi M, Aleyasin A,
Boroumand MA, Abbasi SH, Davoodi S, Mirakhori M. The journal of Tehran University Heart
Center. 2007; 2(3): 161-166.
CONFERENCE
-Poster presentation at the European Human genetics conference, May 28-31, 2011. Amesterdam
RAI, The Netherlands.
“Increased expression of Multidrug resistance Protein 2, MRP2, in colorectal carcinoma tissues
of Iranian patients”
-Poster presentation at the 53rd annual meeting of American society of human Genetic,
November 4-8, 2003 in US.
“Study in folic acid pathway genes alternation in fragile x syndrome in Iran”
– poster presentation, Prevalence of F8 gene mutations and inhibitor development among patients
with severe hemophilia A‘A Report from a Large Hemophilia Center in the IRAN’ at the Iranian
Congress on Thrombosis and Haemostasis 26-28 Aug 2016
-poster presentation, IS-PCR with unusual result in one severe Hemophilia A family with
chroniccognitive impairment, at the Iranian Congress on Thrombosis and Haemostasis 26-28
Aug 2016
-poster presentation, p.Arg2326Glnas a common mutation among Turks Iranian hemophilia A. at
the Iranian Congress on Thrombosis and Haemostasis 26-28 Aug 2016
-poster presentation, Study of Polymorphisms gene FXIII in Iranian patients with deficiency of
coagloution Factor XIII. at the at the Iranian Congress on Thrombosis and Haemostasis 26-28
Aug 2016
-poster presentation, Comparison p.Arg2307Gln missense mutation with
phenotypic determinants in Iranian population. at the Iranian Congress on
Thrombosis and Haemostasis 26-28 Aug 2016
PROJECT DIRECTOR
1-Establishment of retinoblastoma cell lines from Iranian patients. (completed 2016). At Farabi Branch for Stem
Cells, Genetic Department, Farabi Hospital, funding from Tehran University of Medical Sciences
2-Investigation association between polymorphisms of drug resistance genes and the incidence of retinoblastoma in
Iranian population (completed 2015). At Farabi Branch for Stem Cells, Genetic Department, Farabi Hospital,
funding from Tehran University of Medical Sciences
3-Study of ABC transporters protein in retinoblastoma patients undergoing chemotherapy. (Completed 2016) At
Farabi Branch for Stem Cells, Genetic Department, Farabi Hospital, funding from Tehran University of Medical
Sciences